Easom Eric 4

4 · AN2 Therapeutics, Inc. · Filed Feb 28, 2025

Form 4

Period: 2025-02-26

DirectorChief Executive Officer

Transactions

Award
Common Stock
2025-02-26+145,250→ 246,380 total
Award
Stock Option (right to buy)
2025-02-26+290,500→ 290,500 total
Exercise: $1.13Exp: 2035-02-25→ Common Stock (290,500 underlying)

Holdings

Footnotes (6)

[F1]Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
[F2]Includes a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date.
[F3]Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
[F4]Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.
[F5]Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
[F6]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.

Documents

1 file